Faeth Therapeutics, Inc.
FTHNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $96.39M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $7.45$42.14
- Volume (live)
- -
- Avg. volume (3M)
- 424.56K
Faeth Therapeutics (FTH) Stock Price & Financial Analysis
Faeth Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $16.80 - $20.15 |
|---|---|
| 52-Week High | $42.14 |
| 52-Week Low | $7.45 |
| Open | $20.00 |
| Volume (last close) | 353.71K |
| Average Volume (3M) | 424.56K |
| Revenue (TTM) | -4.85M |
|---|---|
| Net Income (TTM) | -195.53M |
| Free Cash Flow (TTM) | -33.86M |
| EPS (TTM) | −$82.67 |
| Return on Equity (ROE) | -113.05% |
| Debt to Equity | 0.00 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 96.39M |
|---|---|
| Shares Outstanding | 5.64M |
| Price to Book (P/B) | 0.56 |
| EV/EBITDA | -0.44 |
| 50-Day MA | $30.82 |
|---|---|
| 200-Day MA | $24.84 |
| 1-Year Change | +92.16% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Faeth Therapeutics at a Glance
As of the Oct 23, 2026 close, Faeth Therapeutics (FTH) has a market capitalization of $96.39M. Over the trailing twelve months it lost $195.53M on revenue of −$4.85M and burned $33.86M of free cash flow.
As of its latest reported balance sheet, it holds $26.90M in cash and securities against $592.00K of debt, a net cash position of $26.31M.
Faeth Therapeutics does not currently pay a dividend.
The share price is up 92.2% over the past year. At $17.08 (the Oct 23, 2026 close) it sits within its 52-week range of $7.45 to $42.14, below its 200-day moving average of $24.84.
Based on 14 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $57.45, 236.4% above the Oct 23, 2026 close.
Frequently Asked Questions About Faeth Therapeutics
What is the current stock price for FTH?
As of the Oct 23, 2026 close, FTH stock trades at $17.08. The 52-week range is $7.45–$42.14, with a day range of $16.80–$20.15.
What is the P/E ratio for FTH?
The P/E ratio (Price-to-Earnings) for FTH is shown in the Key Statistics section. This valuation metric helps compare Faeth Therapeutics, Inc. to industry peers.
Does FTH pay dividends?
Faeth Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for FTH?
Based on ratings from 14 professional analysts over the last 90 days, the consensus for FTH is Buy. The average 12-month price target is $57.45, a 236.4% upside from the Oct 23, 2026 close of $17.08.
What is the market cap of FTH?
As of the Oct 23, 2026 close, Faeth Therapeutics's market capitalization is $96.4M, classifying it as a micro-cap company. Faeth Therapeutics operates in the Healthcare sector within the Biotechnology industry.